Tolga Sütlü
Tolga Sütlü
Assistant Professor at Boğaziçi University
boun.edu.tr üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Delivery of short interfering RNA using endosomolytic cell‐penetrating peptides
P Lundberg, S El‐Andaloussi, T Sütlü, H Johansson, Ü Langel
The FASEB Journal 21 (11), 2664-2671, 2007
3452007
Natural killer cell‐based immunotherapy in cancer: current insights and future prospects
T Sutlu, E Alici
Journal of internal medicine 266 (2), 154-181, 2009
2632009
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
E Alici, T Sutlu, B Björkstrand, M Gilljam, B Stellan, H Nahi, HC Quezada, ...
Blood 111 (6), 3155-3162, 2008
1912008
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor
T Sutlu, B Stellan, M Gilljam, HC Quezada, H Nahi, G Gahrton, E Alici
Cytotherapy 12 (8), 1044-1055, 2010
1062010
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study
L Barkholt, E Alici, R Conrad, T Sutlu, M Gilljam, B Stellan, B Christensson, ...
Immunotherapy 1 (5), 753-764, 2009
1042009
Inhibition of intracellular anti-viral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy
T Sutlu, S Nyström, M Gilljam, B Stellan, SE Applequist, E Alici
Human Gene Therapy 23 (10), 1090-1100, 2012
962012
Triticum durum Metallothionein ISOLATION OF THE GENE AND STRUCTURAL CHARACTERIZATION OF THE PROTEIN USING SOLUTION SCATTERING AND MOLECULAR MODELING
K Bilecen, UH Ozturk, AD Duru, T Sutlu, MV Petoukhov, DI Svergun, ...
Journal of Biological Chemistry 280 (14), 13701-13711, 2005
752005
Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model
E Alici, KV Konstantinidis, T Sutlu, A Aints, G Gahrton, HG Ljunggren, ...
Experimental hematology 35 (12), 1839-1846, 2007
662007
Clinical impact of chromosomal aberrations in multiple myeloma
H Nahi, T Sutlu, M Jansson, E Alici, G Gahrton
Journal of internal medicine 269 (2), 137-147, 2011
462011
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model
B Bestas, PMD Moreno, KEM Blomberg, DK Mohammad, AF Saleh, ...
The Journal of clinical investigation 124 (9), 4067-4081, 2014
432014
The prognostic significance of 8p21 deletion in multiple myeloma
T Sutlu, E Alici, M Jansson, A Wallblom, MS Dilber, G Gahrton, H Nahi
British journal of haematology 144 (2), 266-268, 2009
252009
Retroviral gene transfer into primary human natural killer cells
E Alici, T Sutlu, M Sirac Dilber
Methods Mol Biol 506, 127-37, 2009
142009
Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation
E PAUL, T SUTLU, S DENEBERG, E ALICI, BO BJÖRKSTRAND, ...
Oncology reports 22 (1), 137-142, 2009
112009
Engineering antigen‐specific NK cell lines against the melanoma‐associated antigen tyrosinase via TCR gene transfer
A Parlar, EC Sayitoglu, D Ozkazanc, AM Georgoudaki, C Pamukcu, ...
European journal of immunology 49 (8), 1278-1290, 2019
92019
Deletion of chromosomal region 8p21 confers resistance to bortezomib and is associated with upregulated decoy TRAIL receptor expression in patients with multiple myeloma
AD Duru, T Sutlu, A Wallblom, K Uttervall, J Lund, B Stellan, G Gahrton, ...
PloS one 10 (9), e0138248, 2015
92015
Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS
D Yoyen-Ermis, G Tunali, E Tavukcuoglu, U Horzum, D Ozkazanc, T Sutlu, ...
Scientific Reports 9 (1), 1-11, 2019
82019
Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
EC Sayitoglu, AM Georgoudaki, M Chrobok, D Ozkazanc, BJ Josey, M Arif, ...
Frontiers in Immunology 11, 40, 2020
72020
Ex vivo expansion of natural killer cells: a question of function.
T Sutlu, E Alici
Cytotherapy 13 (6), 767-768, 2011
72011
Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
M Chrobok, CIM Dahlberg, EC Sayitoglu, V Beljanski, H Nahi, M Gilljam, ...
Cancers 11 (1), 69, 2019
62019
Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behçet’s disease severity
T Kahraman, G Gucluler, I Simsek, FC Yagci, M Yildirim, C Ozen, A Dinc, ...
Journal of extracellular vesicles 6 (1), 1284449, 2017
62017
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20